Visualize and Quantify Inversions with dGH SCREEN™
dGH SCREEN™, the original KromaTiD assay, was utilized by NASA in the “Twin’s Study” to measure DNA damage from deep space radiation. NASA’s first foray into “omics” research represented a unique opportunity to develop a next-generation personalized medicine approach to monitoring the health of astronauts.
Today our dGH SCREEN™ platform is still being used by NASA to assess structural rearrangements in the genomes of their best and brightest. dGH SCREEN™ technology is a unique single stranded design allows researchers to visualize and quantify inversions as an inherently more stable biodosimeter than dicentrics, which enables them to obtain data much longer after a radiation event. In addition to greater stability, inversions occur with lower background frequency than other symmetrical aberrations such as translocations, providing fewer false positives and more reliable data.
1/5 - Data from 6 undiagnosed disease patients and 5 of their family members were assessed with dGH paints through the Undiagnosed Disease Consortium. Here, a cell from one of the patients demonstrates a pericentric inversion on chromosome 2 (circled).
2/5 - A cell from another patient from the Undiagnosed Disease Consortium demonstrating a paracentric inversion on chromosome 2 (circled).
3/5 - De novo discovery of a previously unsuspected large inversion (circled) found in roughly 40% of cells on chromosome 2 in an undiagnosed disease patient.
4/5 - Follow up assay in which a probe ladder was designed for the antisense strand, and used in combination with chromatid 2 paint to narrow down the breakpoint region locations. This image demonstrates a normal cell without rearrangements.
5/5 - Antisense ladder and chromatid 2 paint combination assay demonstrating an inversion between the ladder and paint (circled).